101 related articles for article (PubMed ID: 9303052)
1. Postradiotherapy PSA nadirs fail to support dose escalation study in patients with pretreatment PSA values < 10 ng/ml.
Herold D; Hanks G; Movsas B; Hanlon A
Radiat Oncol Investig; 1997; 5(1):15-9. PubMed ID: 9303052
[TBL] [Abstract][Full Text] [Related]
2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
3. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.
Hanks GE; Hanlon AL; Schultheiss TE; Pinover WH; Movsas B; Epstein BE; Hunt MA
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):501-10. PubMed ID: 9635695
[TBL] [Abstract][Full Text] [Related]
5. Long-term results in three-dimensional conformal radiotherapy of localized prostate cancer at moderate dose (66 Gy).
Goldner G; Wachter S; Wachter-Gerstner N; Dieckmann K; Pötter R
Strahlenther Onkol; 2006 Sep; 182(9):537-42. PubMed ID: 16944376
[TBL] [Abstract][Full Text] [Related]
6. External beam radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate carcinoma.
Algan O; Fosmire H; Hynynen K; Dalkin B; Cui H; Drach G; Stea B; Cassady JR
Cancer; 2000 Jul; 89(2):399-403. PubMed ID: 10918172
[TBL] [Abstract][Full Text] [Related]
7. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
Vicini FA; Kestin LL; Martinez AA
Tech Urol; 2000 Jun; 6(2):135-45. PubMed ID: 10798815
[TBL] [Abstract][Full Text] [Related]
8. [Nadir PSA and kinetics of PSA decline between the 3rd and 6th month after external beam radiotherapy for T1 T2 Nx M0 localized prostate cancer: value of the prediction of the risk of biological progression].
Almeras C; Zerbib M; Eschwege F; Debré B
Prog Urol; 2002 Apr; 12(2):219-25. PubMed ID: 12108335
[TBL] [Abstract][Full Text] [Related]
9. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
[TBL] [Abstract][Full Text] [Related]
10. The 100-day PSA: usefulness as surrogate end point for biochemical disease-free survival after definitive radiotherapy of prostate cancer.
Johnstone PA; Williams SR; Riffenburgh RH
Prostate Cancer Prostatic Dis; 2004; 7(3):263-7. PubMed ID: 15289811
[TBL] [Abstract][Full Text] [Related]
11. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
12. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.
Seung SK; Kroll S; Wilder RB; Posner MD; Roach M
Cancer J Sci Am; 1998; 4(3):168-74. PubMed ID: 9612598
[TBL] [Abstract][Full Text] [Related]
13. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
[TBL] [Abstract][Full Text] [Related]
14. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
16. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
17. Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model.
Cavanaugh SX; Kupelian PA; Fuller CD; Reddy C; Bradshaw P; Pollock BH; Fuss M
Cancer; 2004 Jul; 101(1):96-105. PubMed ID: 15221994
[TBL] [Abstract][Full Text] [Related]
18. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of PSA nadir < or =4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer.
Nickers P; Albert A; Waltregny D; Deneufbourg JM
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):73-7. PubMed ID: 16503381
[TBL] [Abstract][Full Text] [Related]
20. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]